OncoTargets and Therapy
Volume 10, 2017 - Issue
Open access
93
Views
12
CrossRef citations to date
0
Altmetric
Original Research
The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia
Vanessa Meier-Stephenson1 Department of Oncology, Cumming School of Medicine, University of Calgary;2 Department of Pediatrics, Alberta Children’s Hospital
, Justin Riemer1 Department of Oncology, Cumming School of Medicine, University of Calgary;2 Department of Pediatrics, Alberta Children’s Hospital
& Aru Narendran1 Department of Oncology, Cumming School of Medicine, University of Calgary;2 Department of Pediatrics, Alberta Children’s Hospital;3 Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC) Laboratory, Calgary, AB, CanadaCorrespondence[email protected]
Pages 2581-2593
|
Published online: 16 May 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.